Changshun Wu Kai Zhou Yan Zheng Dongxiao Lv Miaoqing Zhao Yue Hu Fei Qi Xin Wang Hong Feng
10.3389/fonc.2022.969493
Front Oncol
2022 Dec 2;12:969493.
cd8+pd-l1+ pd-l1 durvalumab hyperprogressive disease non-small cell lung cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/36531043/
Case Reports
PMC9755663
36531043
Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report
2022